<SEC-DOCUMENT>0001213900-26-081983.txt : 20260728
<SEC-HEADER>0001213900-26-081983.hdr.sgml : 20260728
<ACCEPTANCE-DATETIME>20260728073134
ACCESSION NUMBER:		0001213900-26-081983
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260728
DATE AS OF CHANGE:		20260728

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-292303
		FILM NUMBER:		261207534

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea029943502-424b3_kazia.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)<BR>
Registration No. 333-292303 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(to Prospectus dated December 23, 2025) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10,700,211 American Depositary Shares representing
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>5,350,105,500 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ordinary Shares </B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ea029943502_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kazia Therapeutics Limited</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement is being filed to update and supplement
the information contained in the prospectus dated December 23, 2025 (the &ldquo;Prospectus&rdquo;), which forms a part of our Registration
Statement on Form F-1 (Registration No. 333-292303), with the information contained in our current report on Form 6-K, furnished to the
Securities and Exchange Commission on July 28, 2026 (the &ldquo;July 28, 2026 Form 6-K&rdquo;). Accordingly, we have attached the July
28, 2026 Form 6-K to this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus supplement updates and supplements the information
in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including
any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any
inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus
supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ADSs are listed on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;)
under the symbol &ldquo;KZIA.&rdquo; On July 27, 2026, the last reported sale price of the ADSs on Nasdaq was $12.21 per ADS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our securities involves a high degree of risk. See
&ldquo;Risk Factors&rdquo; beginning on page 9 of the Prospectus and the &ldquo;Risk Factors&rdquo; in &ldquo;Item 3. Key Information-D.
Risk Factors&rdquo; of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in
any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus
supplement. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement is July
28, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of July 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 000-29962</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Kazia Therapeutics
Limited.</B></FONT><B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Three International Towers Level 24 300 Barangaroo
Avenue Sydney NSW 2000 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
<B>&nbsp;</B>Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS FORM 6-K REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Press Release</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 28, 2026, Kazia Therapeutics Limited (the &ldquo;Company&rdquo;)
issued a press release titled &ldquo;Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to
Prevent Metastatic Recurrence in Triple-Negative Breast Cancer&rdquo;. A copy of this press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Incorporation by Reference</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company hereby incorporates by reference the information contained
herein, including 99.1, except for the quotes of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into
the Company&rsquo;s registration statements on Form F-3 (File Nos.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000119312523296811/d866423df3.htm">333-276091</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000119312524213396/d867638df3.htm">333-281937</A>&nbsp;and&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1075880/000121390026029366/ea0281732-f3_kazia.htm">333-294392</A>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are furnished as part of this Form 6-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_001"><FONT STYLE="font-size: 10pt">Press Release dated July 28, 2026.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Kazia Therapeutics Limited.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ John Friend</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">John Friend</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: July 28, 2026</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><A NAME="a_001"></A>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kazia Therapeutics Announces the Filing of Provisional Patent
for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Clinically relevant perioperative studies demonstrate
elimination of residual disease and prevention of metastatic spread, supported by complementary translational patient data</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>SYDNEY, Australia, July 28, 2026</B> &ndash;
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology
company developing therapies that reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, announced the
filing of a provisional patent application supporting a novel therapeutic strategy designed to prevent metastatic recurrence in patients
with high-risk early-stage triple-negative breast cancer (TNBC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The patent filing is supported by new preclinical
findings from a model designed to replicate high-risk early-stage TNBC. In the model, standard treatment &mdash;neoadjuvant chemotherapy,
anti-PD-1 immunotherapy and surgical resection &mdash; followed by adjuvant paxalisib reduced&nbsp;residual disease and local recurrence
by 95% (p&lt;0.0001) and lung metastatic burden by 40% (p&lt;0.027).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Complementary translational studies were conducted
on ex vivo tumor samples from patients with high-risk, early-stage TNBC. In these studies, paxalisib completely disrupted (100%) the circulating
tumor cell (CTC) clusters that were detected. Together with emerging clinical observations from the Company&rsquo;s ongoing metastatic TNBC
study, these findings strengthen the translational rationale for advancing paxalisib across multiple stages of disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>A New Strategy to Prevent Metastatic Recurrence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Approximately one-third of patients with Stage
II/III TNBC continue to have residual disease following standard perioperative therapy and remain at high risk of metastatic recurrence.
Current development strategies in this setting are primarily focused on intensifying tumor cell killing through additional cytotoxic therapies
and antibody-drug conjugates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Preventing metastatic recurrence could require
more than eliminating residual tumor cells. It may also require targeting the biological programs that allow those surviving cells to
evade immune surveillance, disseminate and establish metastatic disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Paxalisib represents a differentiated tumor and
immune reprogramming strategy designed to potentially intervene before metastatic relapse becomes clinically established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;For decades, oncology has largely focused
on treating metastatic disease once it appears. The next frontier is preventing metastasis before it begins,&rdquo; said Dr. John Friend
II, Chief Executive Officer of Kazia Therapeutics. &ldquo;Residual disease represents the population of tumor cells most capable of driving
future metastatic relapse. Our new preclinical findings, together with encouraging translational observations from patients receiving
paxalisib-based therapy, support a differentiated strategy focused on reprogramming tumor biology, restoring anti-tumor immunity and preventing
metastatic recurrence. We believe these data significantly expand the potential opportunity for paxalisib beyond advanced disease and
establish a strong scientific and intellectual property foundation for future development in high-risk early breast cancer.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Building on Emerging Clinical Momentum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company&rsquo;s ongoing Phase Ib study evaluating
paxalisib in combination with pembrolizumab (Keytruda&reg;) and chemotherapy in advanced metastatic TNBC generated encouraging preliminary
clinical and translational findings, including objective tumor responses with disruption of CTC clusters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Kazia believes the convergence of these patient
observations with the newly generated perioperative preclinical data strengthens the rationale for advancing paxalisib across multiple
stages of TNBC, from advanced metastatic disease to earlier intervention aimed at reducing residual disease and preventing metastatic
recurrence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Given these findings, the Company is actively
evaluating opportunities to broaden the clinical development of paxalisib into earlier-stage TNBC and expects to provide additional details
regarding its development strategy in the near term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Kazia Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Kazia Therapeutics (NASDAQ:&nbsp;KZIA)
is an oncology-focused drug development company, based in Sydney, Australia. The Company&rsquo;s lead asset, paxalisib, is an investigational
brain penetrant inhibitor of the PI3K/Akt /mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech
in late 2016, paxalisib is or has been the subject of 10 clinical trials. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was
reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Other clinical trials involving paxalisib are
ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several
of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food
and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also granted
FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Additionally, paxalisib was granted Rare Pediatric
Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020 and for atypical teratoid
/ rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which
was licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class
intracellular&nbsp;PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression,
as well as MSETC, a potentially first-in-class SETDB1 inhibitor program intended to restore immune signaling in tumors that have become
resistant to immunotherapy, including checkpoint inhibitors. Both programs are currently in preclinical development. For more information,
please visit&nbsp;www.kaziatherapeutics.com&nbsp;or follow us on X @KaziaTx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This announcement may contain forward-looking
statements, which can generally be identified as such by the use of words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;future,&rdquo; &ldquo;forward,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;potential,&rdquo;
or other similar words.&nbsp;Any statement describing Kazia&rsquo;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the filing and prosecution of the provisional patent application and the establishment of intellectual property protection
for the perioperative therapeutic strategy; the potential of paxalisib to prevent metastatic recurrence in patients with high-risk early-stage
triple-negative breast cancer; expectations regarding the ability of preclinical and translational findings to predict clinical outcomes;
the potential therapeutic benefit of paxalisib to reprogram tumor biology, restore anti-tumor immunity and prevent metastatic recurrence;
the Company&rsquo;s plans to evaluate opportunities to broaden clinical development of paxalisib into earlier-stage TNBC; the ongoing
Phase Ib clinical trial of paxalisib in advanced TNBC, including preliminary clinical and translational findings; the potential of paxalisib
to disrupt circulating tumor cell clusters and reduce residual disease; and the timing and content of future public disclosures regarding
the Company&rsquo;s clinical programs and development strategy.&nbsp;Such statements are based on Kazia&rsquo;s current expectations and projections
about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual
results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with:
the development of early-stage therapeutic programs; the conduct of clinical trials, including the ability to enroll patients and achieve
anticipated enrollment targets; the preliminary nature of preclinical data, which may not be predictive of clinical results in humans;
the preliminary nature of data from small, open-label clinical studies, which may not be predictive of later-stage clinical results; risks
related to regulatory approvals; risks related to Kazia&rsquo;s reliance on third-party collaborators and clinical trial sites;&nbsp;risks related
to the Company&rsquo;s ability to obtain, maintain and protect its intellectual property, including the uncertainty of patent prosecution and
the potential for third-party challenges;&nbsp;risks related to the impact of global economic conditions; and risks related to Kazia&rsquo;s
ability to maintain compliance with the applicable NASDAQ continued listing requirements and standards.&nbsp;These and other risks and
uncertainties are described more fully in Kazia&rsquo;s Annual Report on Form 20-F filed with the SEC, and in subsequent filings with the United
States Securities and Exchange Commission.&nbsp;Kazia undertakes no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events, or otherwise, except as required under applicable law.&nbsp;You should not place undue
reliance on these forward-looking statements, which apply only as of the date of this announcement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Michaela Fawcett<BR>
KCSA Strategic Communications<BR>
<B>mfawcett@kcsa.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ea029943502_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029943502_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ -D# 2(  A$! Q$!_\0
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MJF\26MA+9"[O5!6(=1UJOJ6@^?J/VIIBD>,OD],5HR+9ZS826>\.NWD ]/\
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1WSD_2@!U%-'3.2>E.H __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
